1,850 United Therapeutics Corporation $UTHR Shares Bought by New England Research & Management Inc.

New England Research & Management Inc. lifted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 110.1% during the third quarter, Holdings Channel.com reports. The firm owned 3,530 shares of the biotechnology company’s stock after buying an additional 1,850 shares during the quarter. New England Research & Management Inc.’s holdings in United Therapeutics were worth $1,913,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in UTHR. BlackRock Inc. bought a new stake in United Therapeutics in the 2nd quarter valued at $2,868,735,000. Janus Henderson Group PLC grew its holdings in United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares in the last quarter. Jupiter Topco LLC bought a new position in United Therapeutics during the 2nd quarter worth $450,140,000. Swedbank AB increased its position in United Therapeutics by 0.7% during the 1st quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock worth $193,977,000 after buying an additional 2,350 shares during the period. Finally, Pictet Asset Management Holding SA lifted its holdings in shares of United Therapeutics by 0.8% during the first quarter. Pictet Asset Management Holding SA now owns 309,220 shares of the biotechnology company’s stock worth $183,306,000 after buying an additional 2,383 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on UTHR. Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. The Goldman Sachs Group restated a “sell” rating and issued a $368.00 price target on shares of United Therapeutics in a research note on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of United Therapeutics in a research report on Thursday, October 1st. Morgan Stanley lifted their price objective on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $642.69.

United Therapeutics Stock Performance

Shares of UTHR stock traded down $8.39 during trading on Friday, hitting $533.12. The company had a trading volume of 654,280 shares, compared to its average volume of 992,596. The firm has a market capitalization of $22.87 billion, a P/E ratio of 19.07, a price-to-earnings-growth ratio of 3.87 and a beta of 0.49. United Therapeutics Corporation has a one year low of $409.07 and a one year high of $609.35. The stock’s 50-day moving average price is $513.64 and its 200 day moving average price is $540.40.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter last year, the company earned $6.41 EPS. The company’s revenue was down 1.9% on a year-over-year basis. On average, research analysts anticipate that United Therapeutics Corporation will post 26.40 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $539.99, for a total transaction of $5,129,905.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $175,195,975.57. This represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Paul Mahon sold 8,300 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $544.30, for a total value of $4,517,690.00. Following the completion of the transaction, the executive vice president owned 45,172 shares in the company, valued at $24,587,119.60. The trade was a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 392,028 shares of company stock valued at $202,884,996. Corporate insiders own 8.60% of the company’s stock.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics settled six patent and antitrust disputes with Liquidia, reducing legal uncertainty around Liquidia’s YUTREPIA inhaled treprostinil treatment. The agreement limits YUTREPIA’s label, including excluding pulmonary hypertension associated with interstitial lung disease, which could help protect UTHR’s competitive position. United Therapeutics Settles Litigation And Resets Pulmonary Hypertension Competition
• Positive Sentiment: The settlement is expected to provide United Therapeutics with approximately $380.7 million in payments, while giving investors greater visibility into the competitive landscape for treprostinil therapies. United Therapeutics Stock May Be Undervalued Following the Litigation Settlement
• Positive Sentiment: Traders purchased 12,089 UTHR call options, roughly 220% above average daily volume. The activity signals increased bullish speculation, although options flow does not guarantee sustained buying in the shares.
• Positive Sentiment: Analyst sentiment remains generally favorable. Jefferies reaffirmed a Buy rating with a $728 target, and the broader analyst consensus remains “Moderate Buy,” with targets above recent trading levels.
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.13 million, reducing her holdings by 2.84%. She still retains a substantial position, so the sale may reflect personal financial planning rather than a change in the company’s outlook. United Therapeutics CEO Stock Sale SEC Filing
• Negative Sentiment: EVP Paul Mahon sold 8,300 shares for approximately $4.52 million, cutting his direct stake by 15.52%. The second executive sale disclosed within two days may weigh on sentiment, even though insider transactions alone do not establish a deterioration in fundamentals. United Therapeutics EVP Stock Sale SEC Filing

About United Therapeutics

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.